PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort - Archive ouverte HAL Access content directly
Journal Articles European Journal of Cancer Year : 2024

PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort

Claude Linassier
Brigitte Laguerre
  • Function : Author
  • PersonId : 975632
Marine Gross‐goupil
Gwenaelle Gravis
Laurence Albiges
  • Function : Author
  • PersonId : 1131171

Abstract

Introduction: Papillary renal cell carcinoma (pRCC) is a rare and aggressive cancer with no specifically established therapeutic strategy in the metastatic setting. Combinations of tyrosine kinase and immune checkpoint inhibitors (ICI) are a promising option. We aimed to study the immune landscape of metastatic pRCC, and its interactions with angiogenesis pathways, to search for potential therapeutic targets. Methods: The expression of immune markers (PD -L1, PD -1, PD -L2, LAG -3) and angiogenic pathways (CAIX, cMET), was analyzed by immunohistochemistry on 68 metastatic pRCC retrieved from a retrospective multicenter GETUG cohort. Our primary endpoint was to estimate the prevalence of PD -L1 expression and its prognostic impact in metastatic pRCC. Secondary endpoints included the evaluation of other immune markers (PD -1, PD -L2, and LAG -3) and their association with PD -L1. We also assessed angiogenic markers and their association with PD -L1. Results: Overall, 27.9 % of tumors were PD-L1 positive. PD-L2 was more frequently expressed (45.6 %), PD-1 and LAG-3 were positive in 17.6 % and 19.1 % respectively. None of these markers was correlated with PD-L1 expression. 66 % (45/68) expressed at least one immune marker, and 43 % (29/68) were "double-positive", as they expressed both immune and angiogenic markers. OS was significantly shorter for patients with PD-L1 positive pRCC. A multivariate analysis confirmed a significant association between PD-L1 expression and shorter overall survival (HR = 4.0, p = 0.01). Conclusion: These results reinforce clinical data on the expected benefit of ICI in metastatic pRCC treatment, as PD-L1 expression is a factor of poor prognosis in this multicenter cohort.

Domains

Cancer
Fichier principal
Vignette du fichier
Naffrichoux et al. - 2024 - PD-L1 expression and its prognostic value in metas.pdf (1.52 Mo) Télécharger le fichier
ScienceDirect_files_02Jul2024_13-40-07.505.zip (185.17 Ko) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-04615732 , version 1 (02-07-2024)

Licence

Identifiers

Cite

Jeremie Naffrichoux, Pierre Poupin, William Pouillot, Claude Linassier, Nathalie Rioux-Leclercq, et al.. PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort. European Journal of Cancer, 2024, 205, pp.114121. ⟨10.1016/j.ejca.2024.114121⟩. ⟨hal-04615732⟩
0 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More